Navigation Links
Sinus Dynamics Announced Treatment for MRSA with Nasal Nebulizer and Vancomycin
Date:10/24/2009

Vancomycin is used to treat bacterial infections by stopping or killing the bacteria responsible. When treatment using other antibiotics has failed, Vancomycin is the strongest option available. Now through Sinus Dynamic , Vancomycin is available in an aerosolized topical form which is effective against MRSA.

Westlake Village, CA (PRWEB) October 22, 2009 -- Sinus Dynamics™ announced today that the company has discovered treatment for Methicillin Resistant Staphylococcus Aureus (MRSA) with a nasally inhaled aerosolized form of Vancomycin, which can help patients and hospitals limit exposure to asymptomatic MRSA carriers.

Pharmacists at Sinus Dynamic can help the medical professionals address one of the largest fears of physicians, hospital administrators and patients alike (Hospital Acquired Infections). The Centers for Disease Control and Prevention estimates that hospital acquired infections are a direct result of 90,000 patient deaths each year in the U.S.A., while other organizations claim that the number is much higher.

Sinus Dynamics is the nation's leading compounding pharmacy specializing exclusively in the research and development of aerosolized formulas to treat bacterial and fungal sinus infections, sinus inflammation, and acute and chronic sinusitis. Sinus Dynamics treatments are self-administered by the patient using a small lightweight, electronic nebulizer. This medical device creates a 3.2 micron medicated mist, consisting of antibiotic, anti-fungal or anti-inflammatory medications. The medicated mist penetrates the sinus cavities to topically treat sinuses infected with MRSA or any other bacterial or fungal infection. With industry leading technology that enables physicians from across the country to prescribe our topical treatment method for their refractory sinus patients; Sinus Dynamics has the experience and resources in place to confront MRSA at its so
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmacy Compounds Liquid Mupirocin for the Chronic Sinusitis Patient
2. SyntheMed Announces FDA Clearance of SinusShield(TM)
3. Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation
4. Cellular Dynamics International Appoints Leroy Hood, M.D., Ph.D., and George Church, Ph.D., to its Scientific Advisory Board
5. Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
6. Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
7. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
8. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
9. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
10. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
11. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will release ... 30, 2014, after market close on Thursday, August 14, 2014 ... the market opening on Friday, August 15, 2014, at 8:00 ... Standard Time) to review the Company,s financial results and provide ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today ... a presentation to investors on Tuesday, July 29, ...  The presentation will include an overview of Asterias, ... the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least ...
(Date:7/24/2014)... of Engineering at the University of Delaware, is ... in energy engineering, environmental sustainability and electronics. , ... rock with a well-defined, crystalline structure. At the ... decided that zeolites can separate molecules with size ... (one-tenth of a nanometer), making them useful to ...
(Date:7/24/2014)... SRI International has been awarded a new ... Allergy and Infectious Diseases (NIAID), part of the National ... therapies for HIV infection and AIDS. The contract supports ... and the complications and opportunistic infections associated with the ... of HIV. According to the World ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... Educational program offers unique resources to empower transplant patients ... ... Oct. 17 Astellas Pharma US,Inc. (Pink Sheets: ALPMF), a ... Society (ITNS), a leading transplant,professional organization, announced a collaborative partnership ...
... to Dominate the Type 2 Diabetes Market, According to a ... New Report from Decision Resources, ... have released a new report finding that Merck,will obtain blockbuster antidiabetic ... uptake of their DPP-IV inhibitor, Januvia.,Januvia will see rapid uptake as ...
... 24, at 1:30 p.m. EDT, ALAMEDA, Calif., ... a biopharmaceutical company developing innovative therapies,for the treatment ... to discuss third quarter results on Wednesday, October ... Kenneth Chahine, Chief Executive,Officer, and Michael Coffee, Chief ...
Cached Biology Technology:Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 2Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 3Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2
(Date:7/25/2014)... been raging this summer and some of the smoke from ... this image collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) ... of smoke has descended over the Great Lakes region of ... fire image from July 23, 2014 (first image feature highlighted ... drifts off southeastward. In the image, it is over ...
(Date:7/25/2014)... healthcare community and remain priority areas that ... the worldwide crisis of obesity and diabetes, ... in diabetes, epidemiology and public health describe ... of diverse intervention programs in this novel ... on "Global Health Perspectives in Prediabetes and ...
(Date:7/25/2014)... shows that the age girls reach puberty is influenced by ... which parent contributes the gene. This is the first ... after birth and details of this study were published today ... first period, known as menarche, is a marker for the ... the onset of menses varies between girls, is an inherited ...
Breaking Biology News(10 mins):What constitutes an effective response to the global 'diabesity' tsunami? 2Could age of first period influence development of diseases in older women? 2
... 2012) Eye injuries in war have changed ... tactics, technology and strategies have evolved. Today,s soldiers ... areas not protected by body armor. Military experts and ... and Ear will convene in Boston, Mass., on Sept. ...
... almost $19 million will help to develop technologies ... the National Human Genome Research Institute (NHGRI), part ... During the past decade, DNA sequencing costs ... technologies and process improvements developed by genomics researchers. ...
... time this morning getting your shoes on or thinking about ... suffering with debilitating diseases such as ALS (Lou Gehrig,s disease) ... breathing and eating -- can be a struggle. They ... hopes to help through research that has just been funded ...
Cached Biology News:New NIH/NHGRI grants to harness nanoscale technologies to cut DNA sequencing costs 2New NIH/NHGRI grants to harness nanoscale technologies to cut DNA sequencing costs 3Neurobiologist Rodal wins New Innovator award 2
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
... Reacts with an early ... infection 3 hours post-infection exhibiting ... reaches peak intensity between 6-24 ... extremely intense coarsely granular staining. ...
... clone 8G8/5 GenBank Accession Number : ... AP-2alpha/gamma fusion protein corresponding to residues 166-223 ... human AP-2γ Formulation: 0.1M Tris-glycine, pH 7.4, ... addition of glycerol to 30% Quality Assurance: ...
Parathyroid Hormone Receptor 2 [PTHR2]...
Biology Products: